|Bid||43.60 x 800|
|Ask||43.87 x 800|
|Day's Range||43.31 - 44.00|
|52 Week Range||36.00 - 46.47|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||22.43|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||1.44 (3.30%)|
|1y Target Est||45.57|
Does the June share price for Pfizer Inc. (NYSE:PFE) reflect what it's really worth? Today, we will estimate the...
Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. Insiders often own a...
Biotech stocks came made upward moves last week after a rangebound period. Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Pfizer Inc. (PFE). On August 10, 2017 the Company disclosed that the U.S. Department of Justice was investigating its wholly-owned subsidiary, Greenstone, advising investors that “[w]e believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry.” Recently, the Company was among those sued in a wide-ranging lawsuit brought by 44 state attorneys general alleging an illegal conspiracy to inflate prices of more than 100 generic drugs, sometimes by more than 1,000%, and stifle competition.
Amag Pharmaceuticals Inc. has received regulatory approval to begin selling Vyleesi, a drug designed to address hypoactive sexual disorder, a condition in which causes low sexual desire and distress in an estimated one in 10 women.
Interestingly, June 21 marks the official start of summer, and the summer months often bring lethargy in the equity markets, particularly on Fridays. That was the case today as stocks, broadly speaking, were mostly listless.Source: Shutterstock To close the week, the S&P 500 fell a scant 0.13%, and the Nasdaq Composite lost 0.24%. The Dow Jones Industrial Average also lost 0.13%. Long-term investors can find some solace on the day of the summer solstice with an article in Barron's today indicating Dow 30,000 could arrive sooner than expected."To stick with our 2025 forecast now would be to suggest that stocks over the next 5½ years will climb just 2.1% a year, plus dividends," according to Barron's. "It's possible, but pessimistic. The Dow could reach 30,000 much sooner than 2025."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe article indicates it is possible the Dow sees 30,000 sometime in 2021, a bullish forecast considering the blue-chip index closed around 26,800 today.That is a long-term forecast. Over the near-term, the Federal Reserve will likely dominate the conversation and that is not surprising. For investors hoping for rate cut this year, good news: Fed funds traders bet on such a move in record fashion this week, according to CNBC. Some Mild WinnersBy the end of the day, just two of the 30 Dow Jones stocks were sporting gains of 1% or more. The clear powerhouse was UnitedHealth Group (NYSE:UNH), which gained 1.82% on new that it is acquiring health-care payments provider Equian LLC for $3.2 billion. * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 That is a drop in the bucket for UnitedHealth, which has a market capitalization of $240 billion and a stellar return for Equian's private equity owner New Mountain, which purchased the company four years ago for just $225 million.Defensive names have been getting some attention here in recent weeks and with good reason. Today, Dow component Walmart (NYSE:WMT), on essentially no news to merit a move like this, jump 0.73% to hit an all-time high. The largest U.S. retailer is up almost 20% year-to-date.Pharmaceuticals giant Pfizer (NYSE:PFE) added 0.88% after the European Commission approved the company's TALZENNA treatment for breast cancer patients. The U.S. Food and Drug Administration (FDA) approved the treatment last October."We are thrilled that we can now offer these patients in Europe, who are often diagnosed at a younger age and have limited treatment options, an effective, once-daily, alternative treatment to chemotherapy," said Pfizer in a statement.Staying in the blue-chip pharmaceuticals space, Merck & Co. (NYSE:MRK) closed modestly lower, but three analysts raised price targets on the stock to $90, $95 and $96, respectively. In either case, that is some decent upside from Merck's Friday close around $84.50. Bottom Line on the Dow Jones TodayWith all the talk about a potential rate cut, investors should not forget that second-quarter earnings season will soon be here. While glum earnings may be baked into the market at current levels, investors should still expect some less-than-positive sentiment around the second-quarter numbers."As of today, the estimated earnings decline for the second quarter for the S&P 500 stands at -2.6%," said FactSet in a note out Friday. "If -2.6% is the actual earnings decline for the quarter, it will mark the first time the index has reported two straight quarters of year-over-year declines in earnings since Q1 2016 and Q2 2016. It will also mark the largest year-over-year decline in earnings since Q2 2016 (-3.2%)."Unfortunately, the same note indicates analysts are ratcheting down third-quarter estimates with the energy and technology sectors looking like the worst offenders.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post Dow Jones Today: A Typical Summer Friday appeared first on InvestorPlace.
Pfizer (NYSE:PFE) has received approval from the European Commission for its TALZENNA a breast cancer drug. This approval follows the medicine's approval by the U.S. Food and Drug Administration in October 2018. "Today's approval of TALZENNA for certain patients with advanced-stage breast cancer and an inherited BRCA mutation is the latest example of our successful precision medicine approach to drug development," said Andreas Penk, regional president, Oncology international developed markets at Pfizer in a statement.
Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Dow Jones component Pfizer could become a leader in colon cancer treatment with its looming $11.4 billion acquisition of biotech company Array BioPharma, an analyst said Wednesday.
GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.
Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
"Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.
The Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) is one of the premier avenues for juicing short-term biotechnology returns and the triple-leveraged fund is doing just that with a gain of 21.21% over the past week. As Monday's news of Pfizer Inc. (NYSE: PFE) acquiring Array BioPharma (NASDAQ: ARRY) indicates, there remains robust appetite among larger, blue-chip biotechnology and pharmaceuticals companies for their more nimble peers, particularly the companies with immunotherapy and oncology exposure. There have been some other catalysts fueling LABU's recent run, including some political help.
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
A sizeable chunk of Tuesday's intraday gain was given back before the closing bell rang, though even then the S&P 500 was able to muster a 0.97% win. But, between the bullish gap and the headlines needed to make it happen, it's anyone's guess as to where things go from here.Source: Allan Ajifo via Wikimedia (Modified)Snap (NYSE:SNAP), parent company of Snapchat, was arguably the most noteworthy winner, rallying nearly 10% after BTIG upped its price target to $20. General Electric (NYSE:GE) did more to help the overall market though, gaining almost 4% after long-term doubter John Inch, analyst with Gordon Haskett, conceded that at the very least, GE wouldn't face insolvency. Fanning those bullish flames is a projection that General Electric expects this year's Paris Air Show to yield at least $35 billion worth of orders.Holding the market back more than any other name was La-Z-Boy (NYSE:LZB), down 1.5% during the regular hours session, but off more than 8% in after-hours action after posting poor fourth-quarter numbers after the closing bell rang.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer Except for GE, none make for great trading prospects headed into Wednesday's trading. And for that matter, stock charts of McCormick & Company (NYSE:MKC), FMC (NYSE:FMC) and Pfizer (NYSE:PFE) all look like better prospects than GE from a risk/reward perspective. Here's why. Pfizer (PFE)A little less than three weeks ago, Pfizer was featured as a name that was about to break out, but would have to clear an incredibly tough hurdle to do so. It did so. Namely, it not only broke above the upper boundary of a falling trading range, but broke above the pivotal 200-day moving average line, plotted in white on both stock charts.It's what has happened in the meantime that merits this second look. Although progress has been slow, thanks to yesterday's renewed strength, PFE is entirely back above the 200-day line and now knocking on the door of another resistance level. A move above that ceiling could prove catalytic, as there are no major technical ceilings left standing in the way. Click to Enlarge * The last line in question is $43.34, marked with a white dashed line on the daily chart. That's where Pfizer peaked in April, and where it peaked earlier this month. Shares are one good day away from moving above it. * Beyond that, plotted in red, the highs around $43.80 are the next most likely stumbling blocks, though it's likely they're not a terribly big factor at this point. * Bolstering the bullish case is how much volume took shape behind yesterday's modest advance. It's a subtle hint there are more bulls waiting in the wings, if they can just find enough to be confident about. McCormick & Company (MKC)McCormick & Company shares were nothing but bullish between January's deep low and the rally through early April … a move that reclaimed a miserable last few weeks of last year and rekindled the bullishness from the bulk of 2018.The past several weeks have been decidedly less bullish though. While still making forward progress, that progress was shallow and only driven by a modestly rising support line. And as of Tuesday, that line is on its last legs, and the sellers are starting to turn into a horde. * 10 Tech Stocks to Buy Now for 2025 Click to Enlarge * The support line in question is marked as a white dashed line on both stock charts, tagging all the key lows going back to early April. You have to look closely to see it, but Tuesday's weakness actually broke under that line. * Simultaneously, yesterday's 1.18% setback dragged MKC under the purple 50-day moving average line, which had served as a support line earlier in the month. * Zooming out to the weekly chart of McCormick & Company we can see weakness has already developed in earnest, even if the trend is still "up." The Chaikin line is en route to fall below zero, and we're just one more bad week away from a bearish MACD crossunder. FMC (FMC)Since the middle of last year, FMC has made several attempts to break above what's become a well-established resistance line right around $80.75. Clearly each attempt has failed, resulting on various levels of selloffs.The buyers are at it again though, and this time the outcome may well be different. This time, the effort is starting out from a point that wasn't so deep in the hole. With less ground to cover just to get into position for a breakout thrust, there's more gas in the tank to actually get the stock over the hump. Click to Enlarge * That "hump" is plotted with a yellow dashed line on both stock charts. Although not perfect resistance, it's clear there's something about that level holding FMC shares back. If it can be hurdled, the buying floodgates could readily open. * Last month's low around $71 is a much healthier start to the effort than the December low near $61 was. * Backing out to see the weekly chart we can readily identify a bullish undertow in the Chaikin line as well as with the fresh MACD crossover.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Big Stock Charts for Wednesday: Pfizer, FMC and McCormick & Company appeared first on InvestorPlace.
NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (PFE).